Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
7.76
+0.02 (0.26%)
Jun 29, 2026, 9:44 AM EDT - Market open
Entrada Therapeutics Employees
Entrada Therapeutics had 152 employees as of December 31, 2025. The number of employees decreased by 31 or -16.94% compared to the previous year.
Employees
152
Change (1Y)
-31
Growth (1Y)
-16.94%
Revenue / Employee
$37,750
Profits / Employee
-$1,092,882
Market Cap
279.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 152 | -31 | -16.94% |
| Dec 31, 2024 | 183 | 24 | 15.09% |
| Dec 31, 2023 | 159 | 29 | 22.31% |
| Dec 31, 2022 | 130 | 16 | 14.04% |
| Dec 31, 2021 | 114 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Lyell Immunopharma | 161 |
| Adagene | 128 |
| Niagen Bioscience | 117 |
| Zentalis Pharmaceuticals | 106 |
| SAB Biotherapeutics | 86 |
| Cartesian Therapeutics | 75 |
| InflaRx | 65 |
TRDA News
- 19 days ago - Entrada Therapeutics Transcript: AGM 2026 - Transcripts
- 21 days ago - Entrada Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 21 days ago - Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim - TheFly
- 21 days ago - Entrada Therapeutics Slides: Corporate presentation - Filings
- 25 days ago - Entrada Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 27 days ago - Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study - GlobeNewsWire
- 27 days ago - Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Entrada Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts